BioNTech revenue and financials
$97.64Change from previous close: +0.76%Absolute change: +$0.74
In the fiscal year ended December 2025, BioNTech reported revenue of €2.87B (+4.32% year over year). The net loss was €1.14B.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +4.32%
- 2025 vs 2024
- Net margin
- -39.6%
- 2024: -24.2%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | 10.5 | -421 | 310 | 781 | 147 | — |
| Depreciation and amortization | 266 | 121 | 165 | 124 | 51.0 | — |
| Capital expenditure | -55.4 | -78.9 | -62.1 | -38.6 | -30.2 | — |
| Investing cash flow | -100 | 2,651 | -2,726 | -925 | -64.4 | — |
| Financing cash flow | -109 | 26.4 | -14.3 | -11.5 | -13.3 | — |
| Share repurchases | -129 | — | — | — | 0.0 | — |
| Debt issued | 37.8 | 38.4 | — | — | 0.0 | 0.0 |
| Debt repaid | -17.1 | -12.0 | -19.0 | -11.5 | -13.3 | — |
| Effect of exchange rates | -3.3 | -3.4 | 1.4 | -21.5 | 9.2 | — |
| Net change in cash | -198 | 2,256 | -2,430 | -156 | 68.8 | — |
| Free cash flow | -44.9 | -500 | 247 | 742 | 116 | — |